In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pharma's Love Affair With Dealmaking: No End In Sight

Executive Summary

The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.


Related Content

Mylan Finally Nabs Meda In Diversification Play
Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers
Finding The Fit For Ophthalmology In The New Pfizer
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza
The Shrinking Value Of Best-In-Class And First-In-Class Drugs
Biosimilars: Improving Patient Access To Biologics While Bending The Cost Curve


Related Companies

Related Deals